| 2016 | A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806) | LUNG CANCER |
| 2011 | A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. | LUNG CANCER |
| 2013 | A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC) | LUNG CANCER |
| 2019 | A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs | Lung Cancer |
| 2006 | A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer | LUNG CANCER |
| 2018 | Added prognostic value of CT characteristics and IASLC/ATS/ERS histologic subtype in surgically resected lung adenocarcinomas | LUNG CANCER |
| 2018 | Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea | LUNG CANCER |
| 2021 | Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer | LUNG CANCER |
| 2020 | AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation | LUNG CANCER |
| 2015 | BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis | LUNG CANCER |
| 2010 | Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial | LUNG CANCER |
| 1994 | Changing trends in histologic types of lung cancer during the last decade(1981-1990) in Korean Hospital-based study | LUNG CANCER |
| 2000 | Characteristics of lung cancer in Korea, 1997 | Lung Cancer |
| 2016 | Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions | LUNG CANCER |
| 2014 | Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma | LUNG CANCER |
| 2018 | Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival | LUNG CANCER |
| 2016 | Clinical course of stage IV invasive mucinous adenocarcinoma of the lung | LUNG CANCER |
| 2023 | Clinical implication of the 2020 International Association for the Study of Lung Cancer histologic grading in surgically resected pathologic stage 1 lung adenocarcinomas: Prognostic value and association with computed tomography characteristics
| LUNG CANCER |
| 2019 | Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer | LUNG CANCER |
| 2016 | Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. | LUNG CANCER |
| 2018 | Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study | LUNG CANCER |
| 2009 | Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT. | LUNG CANCER |
| 2019 | Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy | LUNG CANCER |
| 2007 | Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer | LUNG CANCER |
| 2016 | ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models | LUNG CANCER |
| 2018 | Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation | LUNG CANCER |
| 2020 | Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
| LUNG CANCER |
| 2018 | Genetic and clinicopathologic characteristics of lung adenocarcinoma with tumor spread through air spaces | LUNG CANCER |
| 2018 | Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions | LUNG CANCER |
| 2014 | Immunotherapy in the treatment of non-small cell lung cancer | LUNG CANCER |
| 2017 | Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042) | LUNG CANCER |
| 2014 | Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations | LUNG CANCER |
| 2019 | Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma | LUNG CANCER |
| 2014 | KRAS oncogene substitutions in Korean NSCLC patients: Clinical implication and relationship with pAKT and RalGTPases expression | LUNG CANCER |
| 2023 | Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study | LUNG CANCER |
| 2016 | Limited thymectomy as a potential alternative treatment option for early-stage thymoma: A multi-institutional propensity-matched study | LUNG CANCER |
| 2010 | Lipid raft modulation inhibits NSCLC cell migration through delocalization of the focal adhesion complex | LUNG CANCER |
| 2011 | Lung cancer in never smokers: change of a mindset in the molecular era. | LUNG CANCER |
| 2009 | Lung cancer patients who are asymptomatic at diagnosis show favorable prognosis: a korean Lung Cancer Registry Study | LUNG CANCER |
| 2023 | Management of HER2 alterations in non-small cell lung cancer - The past, present, and future | LUNG CANCER |
| 2023 | Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
| LUNG CANCER |
| 2017 | MYC expression correlates with PD-L1 expression in non-small cell lung cancer | LUNG CANCER |
| 2012 | Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung | LUNG CANCER |
| 2016 | Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer | LUNG CANCER |
| 2017 | Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs | LUNG CANCER |
| 2018 | Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
| LUNG CANCER |
| 2012 | Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas | LUNG CANCER |
| 2023 | Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
| LUNG CANCER |
| 2013 | Personalized therapy on the horizon for squamous cell carcinoma of the lung | LUNG CANCER |
| 2017 | Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers | LUNG CANCER |
| 2018 | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
| LUNG CANCER |
| 2022 | Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
| LUNG CANCER |
| 2013 | Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer | LUNG CANCER |
| 2014 | Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma | LUNG CANCER |
| 2009 | Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. | LUNG CANCER |
| 2013 | Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung | LUNG CANCER |
| 2011 | Prognostic effect of stromal lymphocyte infiltration in thymic carcinoma | LUNG CANCER |
| 2015 | Prognostic factors for cases with no extracranial metastasis in whom brain metastasis is detected after resection of non-small cell lung cancer | LUNG CANCER |
| 2019 | Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung | LUNG CANCER |
| 2009 | Prognostic significance of visceral pleural invasion in the forthcoming (seventh) edition of TNM classification for lung cancer | LUNG CANCER |
